Penn Capital Management Company LLC Invests $841,000 in Palvella Therapeutics, Inc. $PVLA

Penn Capital Management Company LLC purchased a new position in Palvella Therapeutics, Inc. (NASDAQ:PVLA) during the 2nd quarter, Holdings Channel reports. The firm purchased 5,506 shares of the company’s stock, valued at approximately $841,000.

A number of other large investors have also made changes to their positions in PVLA. KBC Group NV bought a new stake in shares of Palvella Therapeutics in the first quarter valued at about $28,000. Northwestern Mutual Wealth Management Co. acquired a new stake in Palvella Therapeutics during the second quarter worth about $35,000. Group One Trading LLC increased its stake in Palvella Therapeutics by 151.5% during the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after acquiring an additional 200 shares during the period. Archer Investment Corp acquired a new position in Palvella Therapeutics in the 2nd quarter valued at approximately $69,000. Finally, Quantbot Technologies LP acquired a new position in Palvella Therapeutics in the 2nd quarter valued at approximately $71,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

Palvella Therapeutics Stock Down 0.2%

NASDAQ:PVLA opened at $149.97 on Friday. The firm has a market cap of $2.16 billion, a PE ratio of -31.05 and a beta of -0.17. Palvella Therapeutics, Inc. has a 12 month low of $49.81 and a 12 month high of $161.38. The company’s 50-day moving average price is $146.01 and its two-hundred day moving average price is $126.90.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.35). On average, research analysts expect that Palvella Therapeutics, Inc. will post -6.36 EPS for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on the company. Canaccord Genuity Group set a $232.00 price objective on Palvella Therapeutics in a report on Wednesday, August 5th. Stephens restated an “overweight” rating and issued a $220.00 target price on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Truist Financial set a $207.00 target price on Palvella Therapeutics in a research report on Wednesday, August 5th. Chardan Capital upgraded shares of Palvella Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Palvella Therapeutics in a report on Monday, June 29th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $209.14.

Insider Buying and Selling

In related news, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $152.21, for a total transaction of $654,807.42. Following the completion of the sale, the chief operating officer directly owned 2,154 shares of the company’s stock, valued at $327,860.34. This trade represents a 66.64% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 17.20% of the stock is currently owned by company insiders.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical?stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small?molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil? and complement?mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.